Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.35 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.35 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194934 | 0.89 | S1PR1 (0.40) | S1PR1PLK4 | |
| SCHEMBL10194696 | 0.88 | CDC7 (0.41) | S1PR1PLK4FGFR1FLT1 | |
| SCHEMBL10194685 | 0.79 | LRRK2 (0.36) | MAP2K4MAPK1MAPKAPK2MAPKAPK3MAPK6 | |
| SCHEMBL10194983 | 0.76 | P2RY14 (0.47) | MAP2K4 | |
| SCHEMBL10194690 | 0.75 | FGFR1 (0.37) | FGFR1FLT1KDRMAP2K4MAPK1 | |
| SCHEMBL10194743 | 0.74 | P2RY14 (0.39) | FGFR1FLT1KDR | |
| SCHEMBL10195053 | 0.73 | STAT3 (0.44) | S1PR1FGFR1FLT1MAP2K4 | |
| SCHEMBL10196959 | 0.73 | HTR2A (0.39) | FGFR1FLT1KDRMAP2K4MAPK1 | |
| SCHEMBL17850463 | 0.73 | HTR2A (0.39) | FGFR1FLT1KDRMAP2K4MAPK1 | |
| SCHEMBL10194860 | 0.71 | FGFR1 (0.39) | FGFR1FLT1KDRMAP2K4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | S1PR1 1280/4885PLK4 1837/4885FGFR1 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.